BBO-8520 is under clinical development by BridgeBio Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BBO-8520’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBO-8520 overview
BBO-8520 is under development for the treatment of K-RAS mutated cancers including non-small cell lung cancer (NSCLC), metastatic colorectal cancer and pancreatic cancer. The drug candidate acts by targeting KRAS G12C mutations. It is administered through oral route.
BridgeBio Pharma overview
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company that primarily focuses on the discovery, creation, testing, and delivery of transformative medicines. The company’s major products include Acoramidis, a TTR stabilizer for transthyretin amyloidosis (ATTR), and NULIBRY (fosdenopterin), a synthetic cPMP for molybdenum cofactor deficiency (MoCD). BridgeBio’s products are used in the medical industry, specifically in the treatment of various genetic diseases and cancers. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its brands include TRUSELTIQ and NULIBRY. The company operates Canada, the US, France, Germany, Switzerland and the UK. BridgeBio is headquartered in Palo Alto, California, the US.
For a complete picture of BBO-8520’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
